Derazantinib
Not approved for people anywhereMeasured in people, not heightBy mouthSmall molecule
A cancer-research compound that blocks the receptor family holding cartilage back, along with two unrelated receptors.
ATP-competitive FGFR inhibitor with additional activity at CSF1R and VEGFR2. Oncology only. The article records no approval for it.
Risks. In a bile duct cancer trial nearly everyone had side effects, most often raised blood phosphate, tiredness and eye problems, and more than one in four had a severe one.
On this page
- At the growth plate, members only
- Risks and side effects, members only
The rest of this page is for members
What has been measured, in whom, with every source, and what it does to the rest of you. And every article in the library.
Join for $11.99Lifetime · 3 of 10 founding spots left
Tax is added at checkout (VAT/GST where it applies).
Renews every month at the current price plus tax until you cancel. Cancel from your account before the next monthly charge to stop it.
Card purchases are sold and charged by Link (Stripe) under Link's terms and refund policy.
Already a member? Sign in
Educational content, not medical advice. Nothing here is a recommendation to take or stop taking anything — talk to a doctor about your own situation.